Abstract
Antibiotics that use novel mechanisms are needed to combat antimicrobial resistance1–3. Teixobactin4 represents a new class of antibiotics with a unique chemical scaffold and lack of detectable resistance. Teixobactin targets lipid II, a precursor of peptidoglycan5. Here we unravel the mechanism of teixobactin at the atomic level using a combination of solid-state NMR, microscopy, in vivo assays and molecular dynamics simulations. The unique enduracididine C-terminal headgroup of teixobactin specifically binds to the pyrophosphate-sugar moiety of lipid II, whereas the N terminus coordinates the pyrophosphate of another lipid II molecule. This configuration favours the formation of a β-sheet of teixobactins bound to the target, creating a supramolecular fibrillar structure. Specific binding to the conserved pyrophosphate-sugar moiety accounts for the lack of resistance to teixobactin4. The supramolecular structure compromises membrane integrity. Atomic force microscopy and molecular dynamics simulations show that the supramolecular structure displaces phospholipids, thinning the membrane. The long hydrophobic tails of lipid II concentrated within the supramolecular structure apparently contribute to membrane disruption. Teixobactin hijacks lipid II to help destroy the membrane. Known membrane-acting antibiotics also damage human cells, producing undesirable side effects. Teixobactin damages only membranes that contain lipid II, which is absent in eukaryotes, elegantly resolving the toxicity problem. The two-pronged action against cell wall synthesis and cytoplasmic membrane produces a highly effective compound targeting the bacterial cell envelope. Structural knowledge of the mechanism of teixobactin will enable the rational design of improved drug candidates.
Subject terms: Mechanism of action, Drug development, Solid-state NMR, Antibiotics, Atomic force microscopy
Using a combination of methods, the mechanism of the antibiotic teixobactin is revealed.
Main
A rapid rise in multidrug-resistant bacteria is a major concern for global health6,7. This threat is exacerbated by a drought in the antibiotic pipeline3,8, with alarmingly few new classes of antibiotics introduced into the clinic over the past three decades.
In 2015, screening of uncultured bacteria from soil samples unearthed teixobactin4, a novel antibiotic with broad activity against multidrug-resistant Gram-positive pathogens such as methicillin-resistant Staphylococcus aureus, Streptococcus pneumoniae and vancomycin-resistant Enterococci4. Studies in animal models of infection suggest that teixobactin is a promising drug lead4,9,10. Teixobactin is an undecapeptide that contains five non-canonical amino acids, including four d-amino acids and the cationic l-allo-enduracididine (End10) localized in a C-terminal depsi-cycle (Fig. 1a and Supplementary Fig. 1). Enduracididine contains a unique five-membered cyclic guanidinium moiety that is rarely found in nature11 and its prominent position at the putative lipid II-binding interface has sparked considerable interest. Several groups have accomplished the complicated synthesis of teixobactin12–14 or its analogues15–17; however, they have not resolved the role of End10 in the mode of action.
Recently, we presented a structural model of the fibril-like complex formed between the synthetic analogue R4L10-teixobactin and lipid II using solid-state NMR (ssNMR)18, which enables the study of membrane-acting drugs under native conditions19. However, no structural information could be obtained for the non-canonical amino acids as these residues were either replaced or could not be 13C,15N-labelled in the synthetic teixobactin and were thus inaccessible by ssNMR. Thus, it remains unclear what role l-allo-enduracididine and other residues such as the cationic N-methyl-d-phenylalanine (Phe1)20,21 have in binding to the target. We also showed that R4L10-teixobactin–lipid II oligomerized into clusters on membrane surfaces18. However, the role of oligomerization in the action of teixobactin remains unclear.
Oligomerization and membrane damage
To make the entire antibiotic amenable to ssNMR studies, we produced uniformly 13C,15N-labelled22 natural teixobactin in its native host Eleftheria terrae. Teixobactin and lipid II form a well-defined complex in liposomes that yields high-quality ssNMR spectra (Fig. 1b and Extended Data Fig. 1a–c). An analysis of the chemical shifts23 shows that the N terminus (Ile2–Ile6) adopts β-strand conformation in the bound state (Fig. 1c), in line with its high rigidity (Extended Data Fig. 2a). We previously reported on a synthetic teixobactin analogue in which β-structuring is caused by the formation of antiparallel teixobactin β-sheets18. For natural teixobactin, a 2D ssNMR 13C–13C spectrum with a long magnetization transfer time that probes distances with a threshold of approximately 8–9 Å (Fig. 1d and Extended Data Fig. 3) strongly supports that natural teixobactin also forms antiparallel β-sheets. We observed an unambiguous head-to-tail contact between Phe1Cα and Ala9Cα. In addition, we observed contacts between N-terminal (Phe1, Ile2 and Ser3) and C-terminal (Ser7 or Ile11) residues. Although we could not resolve whether these contacts were with Ser7 or Ile11, all contacts must be intermolecular given that the distance between these residues within the same β-strand is 12–18 Å and hence well above the NMR distance threshold, and all of these contacts are consistent with antiparallel β-sheets, but not with parallel β-sheets (Extended Data Fig. 4). Using pyrene-tagged lipid II24, we confirmed that oligomers form immediately after the addition of teixobactin (Extended Data Fig. 2b,c). Our data hence demonstrate that oligomerization upon target binding is necessary for the high potency of teixobactin, as N-terminally truncated constructs have drastically reduced activity21.
We used confocal microscopy to probe the accumulation of the complex on the surface of giant unilamellar vesicles (GUVs) doped with Atto 550-tagged lipid II (Fig. 1e and Extended Data Fig. 2e–h). Microscopy images clearly show the formation of micron-sized teixobactin–lipid II oligomers. Remarkably, in 2D slices from the z-stack of the GUVs, we observed pronounced concave membrane perturbations at the oligomerization sites, whereas the rest of the GUV surface maintained a regular morphology. We performed static 31P ssNMR spectroscopy to confirm that lipid II-induced oligomerization causes membrane defects25 (Fig. 1f). Although we obtained the characteristic signal pattern of lamellar membranes in the absence of the drug, incubation with teixobactin markedly changed the signal.
To examine whether teixobactin oligomerization also occurs in bacteria, we visualized Bacillus megaterium cells with a fluorescent teixobactin analogue26 using confocal microscopy (Fig. 1g,h). The formation of clusters in bacteria was fast and pronounced; elongated supramolecular teixobactin structures were observed within 15 min. After 45 min of incubation, clusters showed a more compact shape. However, the small increase in the fluorescence intensity implies that most teixobactin molecules are already involved in clusters after 15 min.
Next, we used high-speed atomic force microscopy (HS-AFM) to study the formation of teixobactin–lipid II oligomers in real time27–29. Within minutes after the addition of teixobactin to lipid membranes doped with lipid II, HS-AFM data show the formation of fibrils on the membrane surface, with a height of 0.8 ± 0.1 nm (Fig. 2a,b, Extended Data Figs. 5 and 6 and Supplementary Videos 1 and 2). Fibrils then associated or laterally folded onto each other, forging a sheet of fibrils, in line with the more compact clusters that we observed at 45 min in bacteria by confocal microscopy (Fig. 1g). Fibrils were solely observed in the presence of both teixobactin and lipid II (Extended Data Figs. 5 and 6). Although fibrils initially formed on top of the membrane, they afterwards descended into the membrane. This caused a sizeable membrane thinning; the fibrillar sheets stabilized approximately 0.5 nm below the membrane surface (Fig. 2c–e and Supplementary Video 3).
Together, HS-AFM, confocal microscopy, fluorescence spectroscopy and ssNMR data demonstrate that teixobactin uses a unique, sequential binding mode that results in the formation of fibrillar complexes that perturb the membrane (Fig. 2f). Initially, in a fast step, teixobactin forms antiparallel β-sheets upon binding of lipid II. These small oligomers then elongate into long fibrils that laterally associate and form compact fibrillar sheets. This mechanism sequesters lipid II, making it unavailable to peptidoglycan biosynthesis. In addition, the formation of clusters favourably affects the pharmacodynamics. The supramolecular fibrils were stable for hours in microscopy experiments and presumably form irreversibly on biological timescales given that samples of the complex yielded similar ssNMR spectra after months of storage at 278 K. Hence, the residence time (inverse of the dissociation rate constant (1/koff)) of teixobactin at its target site is presumably long, enhancing its biological activity30. This also means that teixobactin occupies its target long after the administration of the drug, which could prolong its action and be beneficial for the treatment of slow-growing bacteria31.
The complex interface
We used ssNMR to determine the teixobactin–lipid II interface. Lipid II (Fig. 3a) is composed of a conserved sugar-pyrophosphate (GlcNAc–MurNAc–PPi) part and a pentapeptide whose variation confers resistance to glycopeptide antibiotics such as vancomycin32. We used magic angle spinning 31P ssNMR to examine the interaction between teixobactin and the PPi of lipid II (Fig. 3b). A 1D 31P ssNMR spectrum with lipid II-doped liposomes showed a stark signal shift of PPi upon addition of teixobactin. A 2D 1H31P ssNMR spectrum acquired with a short (1 ms) 1H to 31P magnetization transfer time demonstrated that the backbone amino protons of the depsi-cycle (Thr8-Ile11) directly coordinate the PPi group. A 2D 1H31P spectrum with a longer (2 ms) transfer time showed that the cationic End10 sidechain is in the direct vicinity of the anionic PPi, suggesting a favourable electrostatic interaction.
Next, we determined how teixobactin interacts with the sugar-pentapeptide headgroup of lipid II. For this, we assembled the complex with 13C,15N-lipid II18 and acquired 2D 13C13C PARISxy33 spectra (Fig. 3c). We obtained many interfacial contacts between teixobactin and the MurNAc sugar that is covalently attached to the lipid II PPi group, whereas we could not detect a single clear interfacial contact for the GlcNAc sugar (Fig. 3d). These data show that MurNAc is directly at the interface, whereas GlcNAc is distal. Hence, there is a global resemblance between the lipid II interfaces formed by teixobactin and by synthetic R4L10-teixobactin18, for none of which GlcNAc is a direct interaction partner. However, the interaction with MurNAc is strikingly different for natural teixobactin.
Although the hydrophobic residues Ala9 and Leu10 of R4L10-teixobactin form a loosely defined fuzzy interface with MurNAc, natural teixobactin engages in tight and specific interactions due to the presence of End10, demonstrated by the 11 interfacial End10–MurNAc ssNMR contacts (Fig. 3d and Extended Data Fig. 7a,b). Some interfacial contacts were already visible with a short 13C13C magnetization transfer time of 150 ms, which is clear evidence of a tight interface. The tighter binding of natural teixobactin to lipid II could be confirmed by isothermal titration calorimetry (Fig. 3e and Extended Data Fig. 7d). Compared to R4L10-teixobactin (dissociation constant (Kd) = 0.17 μM ± 0.002), natural teixobactin has a markedly higher binding affinity for lipid II (Kd = 0.08 μM ± 0.008) with a substantially more favourable binding enthalpy (ΔH) that most likely relates to additional hydrogen bonds and electrostatic interactions between End10 and lipid II. Moreover, we observed signals consistent with interfacial contacts between Phe1 and MurNAc in 2D 13C13C spectra, strongly suggesting that the cationic N terminus, which has been shown to be critical for killing activity20,21, is directly involved in the coordination of lipid II.
Teixobactin did not bind to the pentapeptide of lipid II (Fig. 3d) and therefore, unlike vancomycin, is not sensitive to variations in the pentapeptide composition32. This provides a rationale for the ability of teixobactin to avoid development of resistance4,34. Of note, the tight interaction between End10 and MurNAc constrains the flexibility of the pentapeptide (Fig. 3f). Therefore, the pentapeptide is more rigid in the complex with teixobactin than with R4L10-teixobactin, which we show with scalar35 ssNMR experiments (Extended Data Fig. 7c). The obstruction of the conformational space of the pentapeptide by teixobactin might hamper the recognition of lipid II by transglycosylases of the cell wall biosynthesis that bind to the pentapeptide36.
Finally, we determined the membrane topology of lipid II-bound teixobactin using a mobility-edited ssNMR experiment37 in which magnetization from mobile water or lipids is transferred to the rigid antibiotic. In agreement with our previous study18, we found that teixobactin localizes at the water–membrane interface with the hydrophobic residues Ile2, Ile5 and Ile6 partitioned in the bilayer (Extended Data Fig. 8). This is supported by a calculated38 partition coefficient of 5.57 for the three hydrophobic sidechains of the N-terminal tail. Together, our data provide a comprehensive picture of the structure and topology of the complex.
Structure of the complex
Next, we calculated the complex structure using four teixobactin and four lipid II (4 × 4) molecules, which provides a better description of intermolecular interactions than a dimeric (2 × 2) arrangement. Calculations were performed with HADDOCK2.4 (ref. 39) and were based on intermolecular teixobactin–teixobactin and interfacial teixobactin–lipid II ssNMR distance restraints, as well as dihedral ssNMR restraints. We obtained 15 unambiguous interfacial contacts with the MurNAc sugar that define the interface precisely.
We obtained a well-resolved ensemble (2.3 ± 0.6 Å average backbone RMSD (root-mean square deviation) for teixobactin) that shows an antiparallel teixobactin β-sheet that could elongate into fibrils (Fig. 4a and Extended Data Fig. 9a), in agreement with the HS-AFM data. The β-sheet is out of register, creating the space to accommodate lipid II between the termini of the neighbouring β-strands. The hydrophilic (Ser3, Gln4 and Ser7) and hydrophobic (Phe1, Ile2, Ile5 and Ile6) residues of teixobactin are sharply divided above and below the β-sheet, respectively (Fig. 4c), which firmly anchors the complex in the membrane and stabilizes the β-sheet by intermolecular hydrogen bonds (Extended Data Fig. 9b). This separation is enabled by the defined sequence of d-amino and l-amino acids in teixobactin, explaining why changing this sequence drastically curbs the activity15,18.
The interface between teixobactin and the PPi–MurNAc group of lipid II is well defined. In the oligomeric complex, PPi is tightly coordinated by the amino-protons of the depsi-cycle of teixobactin and the cationic N terminus of the neighbouring teixobactin strand. This dual coordination of lipid II by adjacent teixobactin molecules improves the stability of the interface (Fig. 4b), explaining the functional importance of the cationic N terminus20,21. The complex shows a specific teixobactin–MurNAc interaction that is governed by End10, in agreement with our ssNMR and isothermal titration calorimetry data. At the interface, End10 is poised to form hydrogen bonds with the C6-OH group of MurNAc in immediate proximity, which agrees with the short-distance ssNMR contacts that we observed between End10Cζ–MurNAcC6 and End10Cζ–MurNAcC5 (Extended Data Fig. 9c). Moreover, the cationic End10 is close to the anionic PPi, causing favourable electrostatics. The void between the β-strands is closed by the acetyl group of MurNAc, which engages in hydrophobic interactions with the methyl group of Phe1, corroborated by ssNMR contacts of the methyl group to MurNAcC1 and MurNAcC3. Neither GlcNAc nor the pentapeptide of lipid II is directly engaged in any interactions with natural teixobactin. Notably, GlcNAc consistently points downwards in the complex structure (Fig. 4a), suggesting that it interacts with the membrane headgroup region.
Together, these data show that natural teixobactin tightly and specifically binds to the invariable PPi–MurNAc part that is present in several cognate cell wall precursors such as lipid I, lipid II or lipid III (precursor of wall teichoic acid), whereas it shuns the pentapeptide that varies across bacterial strains32. Therefore, natural teixobactin maximizes its target spectrum while minimizing the likelihood of resistance development. Notably, the specific interface between natural teixobactin and PPi–MurNAc contrasts with the fuzzy interface of R4L10-teixobactin, where the hydrophobic residues of the depsi-cycle do not favourably interact with MurNAc.
A hydrophobic wedge splays the membrane
We next probed the stability of the complex structure with molecular dynamics simulations. From simulations, we also thought to gauge how the complex interacts with the membrane. We equilibrated the complex in a hydrated DOPC membrane and then freely evolved the system over 260 ns. The complex remained stable over the entire simulation, which vouches for the quality of the ssNMR structure. The simulation demonstrates the importance of oligomer formation for a stable teixobactin–lipid II interaction. The inner lipid II molecules, which are dual-coordinated by adjacent teixobactin molecules, were more tightly bound than the outer lipid II molecules, which are only mono-coordinated by one teixobactin (Fig. 4d). This behaviour was confirmed in another molecular dynamics simulation of equal duration.
The complex caused a pronounced perturbation of the membrane, which manifests itself in a sharply reduced membrane thickness (2.33 ± 0.23 nm at the complex site compared to 3.82 ± 0.23 nm for the unperturbed membrane) (Fig. 4e–g). Membrane perturbations are caused by the very hydrophobic surface of the teixobacin β-sheet that faces the membrane. The hydrophobic β-sheet surface acts like a wedge that pushes the polar lipid headgroups underneath aside, causing lipids to bend almost parallel to the membrane plane (Extended Data Fig. 10a). The membrane order is additionally perturbed by the concerted action of the highly non-lamellar C55 tails of lipid II, which reach deep into the lipid layer on the opposite side to the complex. It appears that teixobactin hijacks lipid II to help disrupt the membrane. These membrane perturbations are in agreement with the membrane deformation that we detected with microscopy and ssNMR.
In much larger teixobactin–lipid II oligomers that we observe experimentally, the perturbations must certainly be more pronounced than in the simulated building block. We hence hypothesized that the membrane perturbations caused by the supramolecular structure could contribute to the antimicrobial action of teixobactin. Addition of teixobactin to Gram-positive bacteria showed a sharp decrease in the membrane potential40 (Fig. 4h and Extended Data Fig. 10b,c). Membrane depolarization was also observed for nisin, a well-known pore former41, but not for the lipid II binders plectasin42 or vancomycin43. Although less pronounced than for nisin, teixobactin also showed clear effects with Sytox green44, a high-affinity DNA stain that can only traverse damaged membranes. Such effects were again absent for plectasin or vancomycin. Membrane defects using intact bacteria were observed within 10 min, that is, a timescale that coincides with the emergence of clusters in bacteria and of fibrils in HS-AFM studies. Together, ssNMR, HS-AFM, confocal microscopy and computer simulations demonstrate that the formation of teixobactin–lipid II fibrillar structures causes membrane defects that contribute to the killing mechanism of teixobactin. Action against the membrane explains why teixobactin is more effective in killing bacteria than vancomycin, which binds to the pentapeptide of lipid II4.
Discussion
The mechanistic data on teixobactin–lipid II binding uncovered in this study illuminate the unique mode of action of this unusual antibiotic. Settling on the surface of the bacterial membrane, the hydrophobic Ile and d-allo-Ile residues anchor it to the membrane. From the 3D space of the external medium, teixobactin preferentially partitions at the 2D water–membrane interface. The structure of the teixobactin–lipid II complex resolved by ssNMR shows that the enduracididine sidechain tightly binds PPi and the MurNAc sugar. Enduracididine forms strong and selective interactions with the MurNAc hexose but would not be able to form a similar interaction with a sterically different pentose sugar, which explains why teixobactin avoids binding to the PPi-(deoxy)ribose moiety of purine nucleosides that are commonly present in the bacterial environment. Intermittent localization of l-amino and d-amino acids favours the formation of an antiparallel β-sheet interaction between two adjacent teixobactin molecules. The N terminus of teixobactin coordinates PPi of lipid II, contributing to target capture. The β-sheet of teixobactins bound to lipid II grows into a supramolecular fibrillar structure. The formation of this structure is probably irreversible, acting as a sink that further concentrates teixobactin at its site of action. Apart from efficiently and potently sequestering lipid II, the supramolecular structure displaces phospholipids, thinning the membrane and compromising its integrity. The hydrophobic residues anchoring teixobactin to the membrane are short, and unlikely to cause damage when present on isolated molecules. Combined in a supramolecular structure, however, this produces a concentrated hydrophobic patch. Similarly, and perhaps more importantly, concentrating the long C55 hydrophobic tails of lipid II within this hydrophobic patch contributes to the damage, causing ion leaks and a drop in the membrane potential. Teixobactin corrupts its target by converting it into a membrane disruptor, and in this regard, joins a select group of other target-corrupting natural products such as aminoglycosides that cause mistranslation45 and acyldepsipeptide46,47, an activator of proteolysis. Conventional membrane-acting antibiotics such as nisin form pores or carry a large hydrophobic moiety that is sufficient to damage the membrane of both bacteria and eukaryotic cells, causing toxicity. Producing membrane-acting antibiotics that do not harm human cells has thus far proven to be an elusive goal3. The problem of selectivity is elegantly solved in teixobactin by disrupting the membrane only if a supramolecular structure forms, and it only forms if the membrane carries lipid II. The formation of the supramolecular structure by teixobactin is a striking departure from the conventional one ligand–one target paradigm. The dual action of teixobactin in inhibiting peptidoglycan synthesis and disrupting the membrane provides for an effective attack on the bacterial cell envelope, whereas binding to an immutable target produces an antibiotic free of detectable resistance.
Methods
Materials
Phospholipids 1,2-dioleoyl-sn-glycero-3-phosphocholine (C18:1; DOPC) was purchased from Avanti Polar Lipids, Inc.
Sample production
Production of teixobactin
Uniformly 13C,15N-labelled teixobactin was produced by fermentation in its native host Eleftheria terrae. In brief, the isolate was grown from a freezer stock on SMSR4 agar (0.125 g casein digest, 0.1 g potato starch, 1 g casamino acids, 1 g d-glucose, 0.1 g yeast extract, 0.3 g proline, 1 g MgCl2-6H2O, 0.4 g CaCl2-2H2O, 0.02 g K2SO4, 0.56 g TES free acid (2-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]ethanesulfonic acid) per 1 l dIH2O, pH to 7 with KOH and 20 g of bacto agar autoclaved at 121 °C for 45 min) for 9 days at 28 °C. Of biomass, 1 cm2 was transferred to 20 ml of modified Celtone-RAZDAZ (10 g d-glucose U-13C6, #CLM-1396, 1.1 g Celtone Base Powder 13C;15N, #CGM-1030P-CN, 0.5 g l-isoleucine 13C6; 15N, #CNLM-561-H, 10 g MgCl2-6H2O, 4 g CaCl2-2H2O, 0.2 g K2SO4, 5.6 g TES free acid per litre, pH to 7 with KOH and autoclaved at 121 °C for 45 min) and grown at 28 °C for 4 days. All labelled material was purchased from Cambridge Isotope Laboratories. Of the grown liquid culture, 20 ml was transferred to 1 l of modified Celtone-RAZDAZ and grown at 28 °C for 6 days. Biomass was harvested by centrifugation at 4,200 r.p.m. and the pellet was extracted with 1 l of 50% aqueous acetonitrile and the suspension again centrifuged for 30 min. The acetonitrile was removed from the supernatant by rotary evaporation under reduced pressure until only water remained. The mixture was then extracted twice with 1 l of n-BuOH. The organic layer was transferred to a round bottom flask and the n-BuOH was removed by rotary evaporation under reduced pressure. The resulting yellow solid was dissolved in DMSO and subjected to preparatory HPLC (high-performance liquid chromatography) (solid phase:C18, mobile phase:H2O/MeCN/0.1% TFA). The fractions containing teixobactin were then pooled and the acetonitrile was removed by rotary evaporation under reduced pressure. The remaining aqueous mixture was then lyophilized to leave a white powder (trifluoroacetate salt). In addition, a quasi-molecular ion peak of m/z 1,315.8683 for 13C58H9615N15O15 [M+H]+ (calculated 1,315.8706 for 13C58H9615N15O15) was determined by high-resolution electrospray ionization mass spectroscopy, confirming 13C58H9515N15O15 as the molecular formula.
Synthesis and purification of lipid II
Lipid II was produced according to published methods based on enzymatic lipid reconstitution using the lipid II precursors UDP-GlcNAc, UDP-MurNAc-pentapeptide and polyisoprenolphosphate as substrates24. Lysine-form UDP-MurNAc-pentapeptide was extracted from S. simulans 22. 13C,15N-labelled UDP-GlcNAc and UDP-MurNAc-pentapeptide (lysine form) were extracted from S. simulans 22 grown in [13C/15N]-labelled rich medium (Silantes) and supplemented with [U-13C]-d-glucose and [15N]-NH4Cl19. Polyisoprenolphosphate was synthesized via phosphorylation of polyisoprenol obtained from Laurus nobilis48. The headgroup precursors were extracted from bacteria and polyisoprenol was extracted from leaves as previously described49. After synthesis, lipid II was extracted with 2:1 BuOH:(Pyr/acetate; 6 M) and then purified with a DEAE cellulose resin using a salt gradient of 0–600 mM NH4HCO3 with 2:3:1 CHCl3:MeOH:[H2O + salt]. Fractions containing pure lipid II were pooled, dried and dissolved in 2:1 chloroform/methanol. The concentration of lipid II was estimated through an inorganic phosphate determination50.
ssNMR sample preparation
Multi-lamellar vesicles of DOPC doped with 4 mol% lysine-lipid II in buffer (40 mM Na2PO4 and 25 mM NaCl, pH 7.2) were collected by centrifugation (60,000g) and loaded into ssNMR rotors. For 3.2-mm rotors, we used 800 nmol of teixobactin with unlabelled lipid II, whereas we used 400 nmol with labelled lipid II. For 1.3-mm rotors, samples contained 200 nmol of antibiotic for unlabelled lipid II.
ssNMR spectroscopy
1H-detected ssNMR experiments were performed at 60 kHz magic angle spinning (MAS) using magnetic fields of 700 and 950 MHz (1H frequency). 3D CαNH and CONH experiments51 for the sequential assignment of teixobactin were performed with dipolar transfer steps using low-power PISSARRO52 decoupling in all dimensions. 1H-detected 15N T1rho relaxation experiments18,51 were acquired with a 15N spin lock-field of 18 kHz and spin-lock durations of 0, 10, 20, 40, 70 and 100 ms. T1rho trajectories were fit to single exponentials. 2D CC experiments were acquired with PARISxy33,53 recoupling (m = 1) at 950 MHz magnetic field and 18 kHz MAS. A 2D CαN experiment was acquired at 700 MHz, 12 kHz MAS and 5 ms N to C cross-polarization transfer time. To characterize lipid II-bound teixobactin, we used CC magnetization transfer times of 50 and 600 ms. To probe interfacial contacts between 13C,15N-teixobactin and 13C,15N-lipid II, we used CC magnetization transfer times of 50, 150 and 300 ms. The scalar TOBSY35 experiment was acquired at 700 MHz using 8 kHz MAS with 6 ms CC mixing time. The mobility edited H(H)C experiment25 was measured at 700 MHz with 16.5 kHz MAS at a temperature of 300 K using a T2 relaxation filter of 2.5 ms. 1D MAS 31P experiments were acquired at 500 MHz magnetic field and 12 kHz MAS. 2D HP experiments were acquired at 800 MHz and 60 kHz MAS using 1 and 2 ms 1H to 31P cross-polarization contact time. Static 31P ssNMR experiments were acquired at 500 MHz magnetic field without sample spinning. Note that the phosphorus nuclei of lipids give rise to an anisotropic powder pattern signal, whose shape depends on the orientation of lipid headgroups25. Further experimental details of ssNMR experiments are given in the Supplementary Information.
Fluorescence microscopy
GUVs preparation
We used a self-assembled GUV cell, aligned with two titanium electrodes in a closed Teflon chamber (volume = 500 μl). Of 0.5 mM DOPC doped with Atto 550-labelled lipid II (0.1 mol%), 1 μl was brushed on the titanium electrodes. The GUV cell was dried under vacuum. Next, the chamber was filled with 350 μl 0.1 M sucrose solution, the electrodes dipped in and connected to a power supply of a sine wave (2.5 V; 10 Hz; 90 min). Each microscopy slide (m-slide 8 well, Ibidi) was incubated with 350 μl BSA solution (1 mg ml−1) for 1 h. To detach the GUVs, the power supply was changed to square wave (2 V; 2 Hz; 15 min). The slides were washed once with water and 0.1 M glucose solution. The slides were immersed in 300 μl of 0.1 M glucose solution to which 50 μl of GUVs was added. These were incubated for 3 h with 1 μM teixobactin and later observed under a Zeiss LSM 880 confocal microscope. GUVs were imaged using Zeiss LSM 880 with ×63/1.2 NA glycerol and ×100/1.2 NA oil objective lenses. The Atto 550 label appeared red upon excitation by the 560-nm laser. The brightfield was used for detection and location of the GUVs and to observe their shape. Zeiss Zen Black software was used for the analysis of the images.
Bacterial imaging
B. megaterium was grown overnight at 37 °C in LB media. Secondary culture was grown for 3 h until the OD600 = 0.3 was reached. Of cells, 500 μl were centrifuged at 3,000g for 5 min. The supernatant was discarded, and the cells were resuspended in 200 μl solution from a 1 μg ml−1 stock of the fluorescent analogue26 Lys(Bodipy FL)10-teixobactin. The cells were allowed to incubate for the desired timepoints (1 min, 15 min and 45 min) at 37 °C. After incubation, they were centrifuged and washed with buffer (100 mM Na2HPO4 and 18 mM KH2PO4, pH 7.4) three times. For fixing the cells, they were resuspended in a 4% formalin and allowed to incubate at 37 °C for 10 min. They were washed once again with the buffer and resuspended in 200 μl of buffer. Of the stained and fixed cells, 50 μl were then pipetted onto the agarose beds and covered with coverslip. The bacterial coverslips were imaged using Zeiss LSM 700 with a ×100/1.2 NA oil objective lens. Lys(Bodipy FL)10-teixobactin was excited using a 488-nm laser. A z-stack containing 15 planes at a 0.56-μm interval was acquired with 0.1-μm pixel size, and maximum intensity projections were made for analysis and display. Icy software’s Spot detector was used to analyse the images and calculate the average intensity of the clusters in all images54.
Isothermal titration calorimetry
For isothermal titration calorimetry (ITC) measurements large unilamellar vesicles (LUVs) containing lysine-lipid II were prepared by incorporating 2 mol% of lysine-lipid II in DOPC from the stock solution. The lipids were dried under a nitrogen stream and hydrated with buffer (20 mM HEPES and 50 mM NaCl, pH 7) to a lipid-phosphate concentration of 20 mM. Finally, unilamellar vesicles were obtained after ten rounds of extrusion through 200-nm membrane filters (Whatman Nuclepore, Track-Etch Membranes). ITC experiments were performed with the Affinity ITC (TA Instruments-Waters LLC) to determine interaction between LUVs and teixobactin. Teixobactin was diluted in the buffer, to a final concentration of 30 μM. The samples were degassed before use. The chamber was filled with 177 μl of teixobactin, and the LUVs were titrated into the chamber at a rate of 1.96 ml per 150 s with a constant syringe stirring rate of 125 r.p.m. The number of injections was 23. Experiments were performed at 37 °C and analysed using the Nano Analyze Software (TA instruments-Water LLC). All experiments were performed in triplicates. Control experiments were performed with lipid II-free DOPC LUVs. The independent model was used to determine the interaction between teixobactin and lipid II. ITC data of R4L10-teixobactin were previously published18.
Fluorescence spectroscopy
For fluorescence spectroscopy, DOPC LUVs containing 0.5 mol% of pyrene-labelled lipid II in buffer (10 mM Tris-Cl and 100 mM NaCl, pH 8.0) were prepared as described above. All fluorescence experiments were performed with a Cary Eclipse (FL0904M005) fluorometer. All samples (1.0 ml) were continuously stirred in a 10 × 4-mm quartz cuvette and kept at 20 °C. Teixobactin was titrated to the LUVs. Pyrene fluorescence was followed with spectral recordings between 360 and 550 nm (λex350 nm, bandwidth 5 nm). The emission at 380 and 495 nm was recorded and averaged over 50 s, to obtain the values for the monomer and excimer intensity, respectively, to determine the excimer to monomer ratio for all conditions.
HS-AFM imaging
The HS-AFM images were acquired in amplitude modulation tapping mode in liquid using a high-speed atomic force microscope (RIBM). Short cantilevers (approximately 7 μm) with a nominal spring constant of 0.15 N m−1 were used (USC-F1.2-k0.15, NanoWorld). A minimal imaging force was applied by using a small set-point amplitude of 0.8 nm (for a 1 nm free amplitude). The HS-AFM results showing the assembly of teixobactin filaments and membrane deformation were obtained from imaging of supported lipid bilayers on mica. The lipid bilayer was obtained by incubating LUVs containing DOPC and lipid II (prepared as mentioned above) on top of a freshly cleaved mica for 20–30 min. After the incubation period, the mica was cleaned gently using recording buffer (10 mM Tris-Cl and 100 mM NaCl, pH 8.0). Imaging was started on the lipid bilayer surface in recording buffer. Next, a concentrated teixobactin solution was added to reach the desired final teixobactin concentration in the AFM liquid chamber of 40 µl. Images were primarily processed using built-in scripts (RIBM) in Igor Pro (Wavemetrics) and analysed using ImageJ software. The images or videos were corrected minimally for tilt, drift and contrast. Unless otherwise mentioned, the times reported in AFM images are relative to the addition of teixobactin into the imaging chamber. Image acquisition rate varies from 0.5 frames per second to 2 frames per seconds (see Fig. 2, Extended Data Figs. 5, 6, or legends of Supplementary Videos 1 and 2), and the line rate varies from 150 lines per second to 400 lines per second. Control experiments with conventional AFM (JPK Nanowizard) supported the HS-AFM measurements as a similar height of the individual fibrils and their sheets on the membrane was observed. Stated errors are standard deviation.
Permeabilization assay
The bacterial cultures were grown overnight at 30 °C in TSB media for S. simulans and at 37 °C in LB medium for Bacillus subtilis. Secondary cultures were grown for 3 h until OD600 = 0.5 was reached. The bacterial cells were then centrifuged at 1,500g for 10 min at 4 °C and washed twice with 10 ml of buffer (10 mM Tris, 100 mM NaCl, 1 mM MgCl2 and 0.5% glucose, pH 7.2). The bacterial cells were resuspended to an OD600 = 10 in the buffer and used for the experiment. All permeability experiments were performed with a Cary Eclipse (FL0904M005) fluorometer. All samples (1.0 ml) were continuously stirred in a 10 × 4-mm quartz cuvette and kept at 20 °C. For the assay, 1 μl of the bacterial suspension was added to 1 ml of buffer. For the ion leakage assays, 1 μl of the DiSC-2 probe from a 1 mM stock was added to the cuvette and the fluorescence was measured between a wavelength of 650 nm and 670 nm (bandwidth of 5 mm) for 2 min before the addition of the antibiotic and 6 min after. For the Sytox green leakage assays, 1 μl of the Sytox green probe from a 0.25 mM stock was added to the cuvette and the fluorescence was measured between a wavelength of 500 nm and 520 nm (bandwidth of 5 mm) for 2 min before the addition of the antibiotic and 6 min after. All experiments were performed in triplicates. The concentrations of antibiotics used are 10 nM nisin (1× MIC), 10 μM vancomycin (10× MIC) and 0.5 μM plectasin/teixobactin for S. simulans (1× MIC) and 0.2 μM plectasin/teixobactin for B. subtilis (10× MIC).
Structure calculations
Parametrization of teixobactin
Parameters and topology were based on our work on R4L10-teixobactin18, substituted with d-glutamine at position 4 and l-allo-enduracididine at position 10. Parameters for l-allo-enduracididine were based on l-arginine, in which the guanidinium group was cyclized with ring geometry as in 2-keto-enduracididine in Protein Data Bank (PDB) 4JME55. A monomeric teixobactin starting model for HADDOCK structure calculation was then generated in CNS56, using only chemical-shift-derived restraints57. Parameters for lipid II were taken from ref. 58.
Structure calculation protocol
We used HADDOCK version 2.4 (ref. 39) for the structure calculations. An eight-body docking (four lipid II and four teixobactin molecules) was performed using ssNMR-derived distance and dihedral restraints. Seven thousand models were generated in the rigid-body docking stage of HADDOCK, of which the best-scoring 500 were subjected to the flexible refinement protocol of HADDOCK. The resulting models were energy minimized. Default HADDOCK settings were used except for doubling the weight of the distance restraints during all stages of the structure calculation. The final models were further filtered based on the topological requirements (that is, the lipid tails of all lipid II molecules must point in the same direction as the membrane-anchoring residues Ile2, Ile5 and Ile6). This resulted in a final ensemble of 25 structures.
Analysis of calculated structures
Structural and violation statistics of the final 25 structures are discussed in detail in the Supplementary Information. The average backbone RMSD (from the average structure) of the 25 teixobactin molecules in the complex was 2.3 ± 0.6 Å.
Molecular dynamics simulations
Molecular dynamics calculations were performed with GROMACS, version 4.6.3 using the g54a7 forcefield59. We simulated the ssNMR structure of four teixobactin molecules in complex with four lipid II molecules in a hydrated DOPC membrane. The truncated lipid II tail used for the ssNMR structure was manually elongated to C55 tails by transferring coordinates from ref. 60. The topologies for natural teixobactin and lipid II were generated using ATB61. The charges on the PPi group were adapted to those in ref. 58. For the starting system, the complex was placed approximately 0.5 nm (in reference to the teixobactin molecules) above a pre-equilibrated DOPC bilayer62 (extended to 512 lipids) and ten lipids were removed to accommodate the long lipid II tails. The box (dimensions 12.81 × 12.81 × 10 nm) was then rehydrated and the system electrostatically neutralized (total atom number of 120,295). After minimization, the system was equilibrated at 300 K for 1 ns in an NVT ensemble (fixed number of atoms, N, a fixed volume, V, and a fixed temperature, T) using a V-rescale thermostat with a coupling constant of 0.1 ps and a 2-fs time step with strong position restrains (force constant of 10,000 kJ mol−1 nm−2) on the complex. Next, the system was equilibrated for 100 ns in an NPT ensemble (fixed number of atoms, N, a fixed pressure, P, and a fixed temperature, T) with semi-isotropic pressure coupling at 1 bar using a Parrinello–Rahman barostat63. During this equilibration step, position restraints were gradually reduced from 1,000 to 25 kJ mol−1 nm−2. For lipid II tails, position restraints were removed to facilitate their integration into the membrane. Afterwards, the system was freely evolved in two independent simulations for 287 and 267 ns without applying ssNMR distance restraints. In one of the two simulations, chemical-shift-derived dihedral restraints57 were applied to residues 2–6 of the teixobactin molecules with a constant of force of 100 kJ mol−1 nm−2.
Average atom–atom distances in the ensemble (see Supplementary Tables 5–7) were computed with the GROMACS tool g_dist. The membrane thickness discussed in Fig. 4 was computed with g_lomepro64, considering the phosphorus atoms of DOPC to specify the representative lipid atoms and using a 100 × 100 grid. An additional simulation of 250 ns without teixobactin was performed to get the average thickness of the unperturbed membrane. To back-calculate distances between teixobactin and water or lipid tails, we counted contacts over the free molecular dynamics simulation (from 100 ns to the end of the simulation). Contacts were counted using the GROMACS tool g_mindist for a water or lipid tail atom within a distance of 0.5 nm.
Reporting summary
Further information on research design is available in the Nature Research Reporting Summary linked to this paper.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at 10.1038/s41586-022-05019-y.
Supplementary information
Acknowledgements
This work was funded by the Netherlands Organisation for Scientific Research (NWO; grant numbers 723.014.003 and 711.018.001 to M.W., 680.91.007 to A.M. and 718.015.001 to A.M.J.J.B.). This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement no. 101045485 to M.W.). Experiments at the 950-MHz instrument were supported by μNMR-NL, an NWO-funded Roadmap NMR facility (no. 184.032.207). Support by Instruct-ERIC (to M.L. and M.W.) is acknowledged. The present work was part of the research programme of the Netherlands Centre for One Health (www.ncoh.nl). This work has been supported by iNEXT-Discovery (grant number 871037) and BioExcel (grant numbers 675728 and 823830), funded by the Horizon 2020 programme of the European Commission. M.L. acknowledges the support of Progetto Dipartimenti di Eccellenza 2018-2022 of the Department of Chemistry 'Ugo Schiff' of the University of Florence.
Extended data figures and tables
Source data
Author contributions
K.L. and M.W. designed the study. R.S., L.M.B., M.L. and M.W. conducted the NMR experiments. R.S., J.H.L., E.B. and H.D.M. performed the confocal microscopy studies. S.M., A.M. and W.H.R. conducted the AFM studies. R.S. performed the calorimetric studies. R.S., M.G.N.D., J.M.-S., R.A.M.v.B. and E.B. prepared the ssNMR samples and lipid II. C.R.J., M.A.M. and J.S.N. produced fluorescent teixobactin analogues. R.S., X.W. and E.B. performed the bacterial assays. F.L., B.J.A.V., A.M.J.J.B. and M.W. conducted the structure calculations and/or the molecular dynamics simulations. A.J.P., A.L.S., L.L.L., K.L. and D.E.H. produced teixobactin. All authors contributed to data analysis. K.L. and M.W. wrote the manuscript.
Peer review
Peer review information
Nature thanks the anonymous reviewers for their contribution to the peer review of this work.
Data availability
The ssNMR assignments of teixobactin and lipid II have been deposited in the Biological Magnetic Resonance Data Bank (accession number 50938). The PDB structure of the complex has been deposited in the PDB database (PDB code 7QGV). Experimental ssNMR raw data have been deposited in an open repository, Zenondo (10.5281/zenodo.6549335). The source data underlying Figs. 1c,h, 2d, 3e and 4d,h and Extended Data Figs. 2, 5, 6, 8d,f and 10b,c are provided as a Source Data file. Source data are provided with this paper.
Competing interests
A.J.P., A.L.S., L.L.L., D.E.H. and K.L. are employees and consultants of NovoBiotic Pharmaceuticals. All other authors declare no competing interests.
Footnotes
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Extended data
is available for this paper at 10.1038/s41586-022-05019-y.
Supplementary information
The online version contains supplementary material available at 10.1038/s41586-022-05019-y.
References
- 1.Brown ED, Wright GD. Antibacterial drug discovery in the resistance era. Nature. 2016;529:336–343. doi: 10.1038/nature17042. [DOI] [PubMed] [Google Scholar]
- 2.World Health Organization. Antibacterial Agents in Clinical and Preclinical Development: an Overview and Analysis (WHO, 2020).
- 3.Lewis K. The science of antibiotic discovery. Cell. 2020;181:29–45. doi: 10.1016/j.cell.2020.02.056. [DOI] [PubMed] [Google Scholar]
- 4.Ling LL, et al. A new antibiotic kills pathogens without detectable resistance. Nature. 2015;517:455–459. doi: 10.1038/nature14098. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Breukink E, de Kruijff B. Lipid II as a target for antibiotics. Nat. Rev. Drug Discov. 2006;5:321–332. doi: 10.1038/nrd2004. [DOI] [PubMed] [Google Scholar]
- 6.O’Neill, J. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. jpiamrhttp://www.jpiamr.eu/wpcontent/uploads/2014/12/AMR-Review-Paper-Tackling-a-crisis-for-the-health-and-wealth-of-nations_1-2.pdf (2014).
- 7.Cassini A, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect. Dis. 2019;19:56–66. doi: 10.1016/S1473-3099(18)30605-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Cooper MA, Shlaes D. Fix the antibiotics pipeline. Nature. 2011;472:32. doi: 10.1038/472032a. [DOI] [PubMed] [Google Scholar]
- 9.Lawrence WS, et al. Teixobactin provides protection against inhalation anthrax in the rabbit model. Pathogens. 2020;9:773. doi: 10.3390/pathogens9090773. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Parmar A, et al. Design and syntheses of highly potent teixobactin analogues against Staphylococcus aureus, methicillin-resistant Staphylococcus aureus (MRSA), and vancomycin-resistant Enterococci (VRE) in vitro and in vivo. J. Med. Chem. 2018;61:2009–2017. doi: 10.1021/acs.jmedchem.7b01634. [DOI] [PubMed] [Google Scholar]
- 11.Atkinson DJ, Naysmith BJ, Furkert DP, Brimble MA. Enduracididine, a rare amino acid component of peptide antibiotics: natural products and synthesis. Beilstein J. Org. Chem. 2016;12:2325–2342. doi: 10.3762/bjoc.12.226. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Zong Y, et al. Gram-scale total synthesis of teixobactin promoting binding mode study and discovery of more potent antibiotics. Nat. Commun. 2019;10:3268. doi: 10.1038/s41467-019-11211-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Jin K, et al. Total synthesis of teixobactin. Nat. Commun. 2016;7:12394. doi: 10.1038/ncomms12394. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Giltrap AM, et al. Total synthesis of teixobactin. Org. Lett. 2016;18:2788–2791. doi: 10.1021/acs.orglett.6b01324. [DOI] [PubMed] [Google Scholar]
- 15.Parmar A, et al. Teixobactin analogues reveal enduracididine to be non-essential for highly potent antibacterial activity and lipid II binding. Chem. Sci. 2017;8:8183–8192. doi: 10.1039/C7SC03241B. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Yang H, Pishenko AV, Li X, Nowick JS. Design, synthesis, and study of lactam and ring-expanded analogues of teixobactin. J. Org. Chem. 2020;85:1331–1339. doi: 10.1021/acs.joc.9b02631. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Jad YE, et al. Synthesis and biological evaluation of a teixobactin analogue. Org. Lett. 2015;17:6182–6185. doi: 10.1021/acs.orglett.5b03176. [DOI] [PubMed] [Google Scholar]
- 18.Shukla R, et al. Mode of action of teixobactins in cellular membranes. Nat. Commun. 2020;11:2848. doi: 10.1038/s41467-020-16600-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Medeiros-Silva J, et al. High-resolution NMR studies of antibiotics in cellular membranes. Nat. Commun. 2018;9:3963. doi: 10.1038/s41467-018-06314-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Monaim S, et al. Investigation of the N-terminus amino function of Arg10-teixobactin. Molecules. 2017;22:1632. doi: 10.3390/molecules22101632. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Yang H, Chen KH, Nowick JS. Elucidation of the teixobactin pharmacophore. ACS Chem. Biol. 2016;11:1823–1826. doi: 10.1021/acschembio.6b00295. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Oster C, et al. Structural studies suggest aggregation as one of the modes of action for teixobactin. Chem. Sci. 2018;9:8850–8859. doi: 10.1039/C8SC03655A. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Wang Y. Probability-based protein secondary structure identification using combined NMR chemical-shift data. Protein Sci. 2002;11:852–861. doi: 10.1110/ps.3180102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Breukink E, et al. Lipid II is an intrinsic component of the pore induced by nisin in bacterial membranes. J. Biol. Chem. 2003;278:19898–19903. doi: 10.1074/jbc.M301463200. [DOI] [PubMed] [Google Scholar]
- 25.Wang T, Cady SD, Hong M. NMR determination of protein partitioning into membrane domains with different curvatures and application to the influenza M2 peptide. Biophys. J. 2012;102:787–794. doi: 10.1016/j.bpj.2012.01.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Morris MA, et al. Visualizing the mode of action and supramolecular assembly of teixobactin analogues in Bacillus subtilis. Chem. Sci. 2022;13:7747–7754. doi: 10.1039/D2SC01388F. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Kodera N, Yamamoto D, Ishikawa R, Ando T. Video imaging of walking myosin V by high-speed atomic force microscopy. Nature. 2010;468:72–76. doi: 10.1038/nature09450. [DOI] [PubMed] [Google Scholar]
- 28.Maity S, et al. Caught in the act: mechanistic insight into supramolecular polymerization-driven self-replication from real-time visualization. J. Am. Chem. Soc. 2020;142:13709–13717. doi: 10.1021/jacs.0c02635. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Valbuena A, Maity S, Mateu MG, Roos WH. Visualization of single molecules building a viral capsid protein lattice through stochastic pathways. ACS Nano. 2020;14:8724–8734. doi: 10.1021/acsnano.0c03207. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Copeland RA, Pompliano DL, Meek TD. Drug-target residence time and its implications for lead optimization. Nat. Rev. Drug Discov. 2006;5:730–739. doi: 10.1038/nrd2082. [DOI] [PubMed] [Google Scholar]
- 31.Lewis K. Persister cells. Annu. Rev. Microbiol. 2010;64:357–372. doi: 10.1146/annurev.micro.112408.134306. [DOI] [PubMed] [Google Scholar]
- 32.Munch D, Sahl HG. Structural variations of the cell wall precursor lipid II in Gram-positive bacteria—impact on binding and efficacy of antimicrobial peptides. Biochim. Biophys. Acta. 2015;1848:3062–3071. doi: 10.1016/j.bbamem.2015.04.014. [DOI] [PubMed] [Google Scholar]
- 33.Weingarth M, Bodenhausen G, Tekely P. Broadband magnetization transfer using moderate radio-frequency fields for NMR with very high static fields and spinning speeds. Chem. Phys. Lett. 2010;488:10–16. doi: 10.1016/j.cplett.2010.01.072. [DOI] [Google Scholar]
- 34.Lloyd DG, Schofield BJ, Goddard MR, Taylor EJ. De novo resistance to Arg10-teixobactin occurs slowly and is costly. Antimicrob. Agents Chemother. 2020;65:e01152-20. doi: 10.1128/AAC.01152-20. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Baldus M, Meier BH. Total correlation spectroscopy in the solid state. The use of scalar couplings to determine the through-bond connectivity. J. Magn. Reson. A. 1996;121:65–69. doi: 10.1006/jmra.1996.0137. [DOI] [Google Scholar]
- 36.Huang CY, et al. Crystal structure of Staphylococcus aureus transglycosylase in complex with a lipid II analog and elucidation of peptidoglycan synthesis mechanism. Proc. Natl Acad. Sci. USA. 2012;109:6496–6501. doi: 10.1073/pnas.1203900109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Doherty T, Hong M. 2D 1H–31P solid-state NMR studies of the dependence of inter-bilayer water dynamics on lipid headgroup structure and membrane peptides. J. Magn. Reson. 2009;196:39–47. doi: 10.1016/j.jmr.2008.10.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Ghose AK, Viswanadhan VN, Wendoloski JJ. Prediction of hydrophobic (lipophilic) properties of small organic molecules using fragmental methods: an analysis of ALOGP and CLOGP methods. J. Phys. Chem. A. 1998;102:3762–3772. doi: 10.1021/jp980230o. [DOI] [Google Scholar]
- 39.van Zundert GCP, et al. The HADDOCK2.2 web server: user-friendly integrative modeling of biomolecular complexes. J. Mol. Biol. 2016;428:720–725. doi: 10.1016/j.jmb.2015.09.014. [DOI] [PubMed] [Google Scholar]
- 40.Zhang L, Dhillon P, Yan H, Farmer S, Hancock RE. Interactions of bacterial cationic peptide antibiotics with outer and cytoplasmic membranes of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2000;44:3317–3321. doi: 10.1128/AAC.44.12.3317-3321.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Breukink E, et al. Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic. Science. 1999;286:2361–2364. doi: 10.1126/science.286.5448.2361. [DOI] [PubMed] [Google Scholar]
- 42.Schneider T, et al. Plectasin, a fungal defensin, targets the bacterial cell wall precursor lipid II. Science. 2010;328:1168–1172. doi: 10.1126/science.1185723. [DOI] [PubMed] [Google Scholar]
- 43.McCormick MH, McGuire JM, Pittenger GE, Pittenger RC, Stark WM. Vancomycin, a new antibiotic. I. Chemical and biologic properties. Antibiot. Annu. 1955;3:606–611. [PubMed] [Google Scholar]
- 44.Roth BL, Poot M, Yue ST, Millard PJ. Bacterial viability and antibiotic susceptibility testing with SYTOX green nucleic acid stain. Appl. Environ. Microbiol. 1997;63:2421–2431. doi: 10.1128/aem.63.6.2421-2431.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Davis BD, Chen LL, Tai PC. Misread protein creates membrane channels: an essential step in the bactericidal action of aminoglycosides. Proc. Natl Acad. Sci. USA. 1986;83:6164–6168. doi: 10.1073/pnas.83.16.6164. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Brotz-Oesterhelt H, et al. Dysregulation of bacterial proteolytic machinery by a new class of antibiotics. Nat. Med. 2005;11:1082–1087. doi: 10.1038/nm1306. [DOI] [PubMed] [Google Scholar]
- 47.Conlon BP, et al. Activated ClpP kills persisters and eradicates a chronic biofilm infection. Nature. 2013;503:365–370. doi: 10.1038/nature12790. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Danilov LL, Druzhinina TN, Kalinchuk NA, Maltsev SD, Shibaev VN. Polyprenyl phosphates—synthesis and structure–activity relationship for a biosynthetic system of Salmonella anatum O-specific polysaccharide. Chem. Phys. Lipids. 1989;51:191–203. doi: 10.1016/0009-3084(89)90006-6. [DOI] [PubMed] [Google Scholar]
- 49.Kohlrausch U, Holtje JV. One-step purification procedure for Udp-N-acetylmuramyl-peptide murein precursors from Bacillus cereus. FEMS Microbiol. Lett. 1991;78:253–258. doi: 10.1111/j.1574-6968.1991.tb04451.x. [DOI] [PubMed] [Google Scholar]
- 50.Rouser G, Fleischer S, Yamamoto A. Two dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids. 1970;5:494–496. doi: 10.1007/BF02531316. [DOI] [PubMed] [Google Scholar]
- 51.Jekhmane S, et al. Shifts in the selectivity filter dynamics cause modal gating in K+ channels. Nat. Commun. 2019;10:123. doi: 10.1038/s41467-018-07973-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Weingarth M, Bodenhausen G, Tekely P. Low-power decoupling at high spinning frequencies in high static fields. J. Magn. Reson. 2009;199:238–241. doi: 10.1016/j.jmr.2009.04.015. [DOI] [PubMed] [Google Scholar]
- 53.Weingarth M, Demco DE, Bodenhausen G, Tekely P. Improved magnetization transfer in solid-state NMR with fast magic angle spinning. Chem. Phys. Lett. 2009;469:342–348. doi: 10.1016/j.cplett.2008.12.084. [DOI] [Google Scholar]
- 54.de Chaumont F, et al. Icy: an open bioimage informatics platform for extended reproducible research. Nat. Methods. 2012;9:690–696. doi: 10.1038/nmeth.2075. [DOI] [PubMed] [Google Scholar]
- 55.Burroughs AM, et al. Structural and functional characterization of MppR, an enduracididine biosynthetic enzyme from streptomyces hygroscopicus: functional diversity in the acetoacetate decarboxylase-like superfamily. Biochemistry. 2013;52:4492–4506. doi: 10.1021/bi400397k. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Nederveen AJ, et al. RECOORD: a recalculated coordinate database of 500+ proteins from the PDB using restraints from the BioMagResBank. Proteins. 2005;59:662–672. doi: 10.1002/prot.20408. [DOI] [PubMed] [Google Scholar]
- 57.Shen Y, Bax A. Protein backbone and sidechain torsion angles predicted from NMR chemical shifts using artificial neural networks. J. Biomol. NMR. 2013;56:227–241. doi: 10.1007/s10858-013-9741-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Hsu ST, et al. The nisin–lipid II complex reveals a pyrophosphate cage that provides a blueprint for novel antibiotics. Nat. Struct. Mol. Biol. 2004;11:963–967. doi: 10.1038/nsmb830. [DOI] [PubMed] [Google Scholar]
- 59.Schmid N, et al. Definition and testing of the GROMOS force-field versions 54A7 and 54B7. Eur. Biophys. J. 2011;40:843–856. doi: 10.1007/s00249-011-0700-9. [DOI] [PubMed] [Google Scholar]
- 60.Koch DC, Schmidt TH, Sahl HG, Kubitscheck U, Kandt C. Structural dynamics of the cell wall precursor lipid II in the presence and absence of the lantibiotic nisin. Biochim. Biophys. Acta. 2014;1838:3061–3068. doi: 10.1016/j.bbamem.2014.07.024. [DOI] [PubMed] [Google Scholar]
- 61.Malde AK, et al. An automated force field topology builder (ATB) and repository: version 1.0. J. Chem. Theory Comput. 2011;7:4026–4037. doi: 10.1021/ct200196m. [DOI] [PubMed] [Google Scholar]
- 62.Poger D, Mark AE. On the validation of molecular dynamics simulations of saturated and cis-monounsaturated phosphatidylcholine lipid bilayers: a comparison with experiment. J. Chem. Theory Comput. 2010;6:325–336. doi: 10.1021/ct900487a. [DOI] [PubMed] [Google Scholar]
- 63.Parrinello M, Rahman A. Polymorphic transitions in single crystals: a new molecular dynamics method. J. Appl. Phys. 1981;52:7182–7190. doi: 10.1063/1.328693. [DOI] [Google Scholar]
- 64.Gapsys V, de Groot BL, Briones R. Computational analysis of local membrane properties. J. Comput. Aided Mol. Des. 2013;27:845–858. doi: 10.1007/s10822-013-9684-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Medeiros-Silva J, et al. 1H-detected solid-state NMR studies of water-inaccessible proteins in vitro and in situ. Angew. Chem. Int. Ed. Engl. 2016;55:13606–13610. doi: 10.1002/anie.201606594. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Yang H, Wierzbicki M, Du Bois DR, Nowick JS. X-ray crystallographic structure of a teixobactin derivative reveals amyloid-like assembly. J. Am. Chem. Soc. 2018;140:14028–14032. doi: 10.1021/jacs.8b07709. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The ssNMR assignments of teixobactin and lipid II have been deposited in the Biological Magnetic Resonance Data Bank (accession number 50938). The PDB structure of the complex has been deposited in the PDB database (PDB code 7QGV). Experimental ssNMR raw data have been deposited in an open repository, Zenondo (10.5281/zenodo.6549335). The source data underlying Figs. 1c,h, 2d, 3e and 4d,h and Extended Data Figs. 2, 5, 6, 8d,f and 10b,c are provided as a Source Data file. Source data are provided with this paper.